Group 2E: HER2+ Breast Cancer; Predictive Biomarkers

Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #P4-02-01

Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer

Poster author Emanuela Ferraro, M.D. will attend this session

Poster #P4-02-30:

Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer

Mentor: Victoria Goldberg

Victoria Goldberg has been living with Triple Positive MBC since January 2014.  The side effects of the treatment forced her to stop working in the stressful and grueling field of finance earlier than she had planned. She was not ready for retirement and felt a desire to assist others who live daily with this dreadful disease. Advocacy gave her that missing structure and purpose. It felt “right.”  She came to SHARE in 2017, first as a BC helpline volunteer, and later as a founder and manager of TalkMets, SHARE’s dedicated helpline for those living with MBC, and a support group facilitator. In July 2020, Victoria joined the team behind the Our MBC Life podcast.  She is one of the senior producers and is trying her hand at sound editing, graphic design, and co-hosting.  Victoria enjoys working with peers and other stakeholders in the metastatic breast cancer field. She is a member of the MBC Alliance and a graduate of the 2018 NBCC’s Project LEAD. Victoria resides in New York City never forgetting that she is living with an advanced disease, but it’s no longer on the forefront of her life.

Scientist: Julia Foldi, M.D., Ph.D.

Julia trained as a researcher in immunology prior to switching careers slightly to become a physician. She completed her Oncology training at Yale University, where she first interacted with patient advocates while developing her first clinical trial protocol. Julia recently moved to the University of Pittsburgh to begin her first faculty position as a Breast Medical Oncologist. In her new role as a clinical and translational breast cancer researcher, she is hoping to continue developing her relationships with local and national patient advocacy organizations and help connect other physician and scientists with patient advocates. She hopes to use these connections in her practice and research to develop patient-centered clinical studies and to ensure equitable access to evidence-based and state-of-the-art care as well as the ability to participate in research for all patients affected by breast cancer and other malignancies.

Twitter: @JuliaFoldiMD